

**Recombinant SARS-CoV-2 Covid-19 PL-Pro**

<b>Catalog No :</b>	YD2186
<b>Reactivity :</b>	Human virus
<b>Applications :</b>	ELISA ECL Immunogold
<b>Purity :</b>	>90% as determined by SDS-PAGE
<b>Fields :</b>	For research use only .Not for use in clinical diagnostic procedures.
<b>Gene Name :</b>	ORF1ab
<b>Protein Name :</b>	nsp3,PL-PRO,Papain-like proteinase,Peptidase C16 domain
<b>Human Gene Id :</b>	QHD43415.1
<b>Source :</b>	E.coli
<b>Dilution :</b>	Testing in progress
<b>Concentration :</b>	>90% as determined by SDS-PAGE
<b>Storage Stability :</b>	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week . Store at -20 to -80 °C for twelve months from the date of receipt.
<b>Molecularweight :</b>	38.59kDa
<b>Observed Band :</b>	34kDa
<b>Background :</b>	Recombinant SARS-CoV-2 PL-Pro is produced by E.coli expression system and the target gene encoding Glu1564-Ile1877 is expressed with N-His Tag
<b>Function :</b>	The coronaviral proteases, papain-like protease (PLpro) and 3C-like protease (3CLpro), are attractive antiviral drug targets because they are essential for coronaviral replication. PLpro has the additional function of stripping ubiquitin and ISG15 from host-cell proteins to aid coronaviruses in their evasion of the host innate immune responses. Targeting PLpro with antiviral drugs may have an advantage in not only inhibiting viral replication but also inhibiting the

dysregulation of signaling cascades in infected cells that may lead to cell death in surrounding, uninfected cells.

---

## Products Images